Navigation Links
Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development

SEATTLE, Feb. 7 /PRNewswire/ -- Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced the appointment of David Drajeske as Director of Business Development.

Drajeske brings more than a decade of business development experience in the life sciences industry. He formerly served as Vice President of Business Development for Helix BioMedix, a publicly traded biotechnology company, from 2004 to 2006. While at Helix, Drajeske was involved in the initiation and negotiation of multiple development collaborations. Prior to Helix, Drajeske served as Manager of Business Development for Immunex Corporation. He has also served as Senior Manager, Business Development and Alliance Management for Thermogen, Inc. and Medichem Life Sciences. Drajeske received an M.S. in Biotechnology from Northwestern University's Kellogg Center for Biotechnology and a B.S. in chemical engineering from Purdue University.

"David will be instrumental in our outreach activities aimed at educating potential partners about Koronis' innovative Viral Decay Acceleration therapeutics," said Donald Elmer, Chairman and interim Chief Executive Officer of Koronis. "His business development experience will be an asset to our Company."

About Koronis

Koronis Pharmaceuticals, Inc. is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate, KP-1461 for the treatment of human immunodeficiency virus (HIV), is currently being evaluated in a Phase 2 trial. In addition to KP-1461, the Company has products in development for the treatment of hepatitis C and RSV. For more information on Koronis, please visit

SOURCE Koronis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
2. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
5. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
10. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
11. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... recipients of 13 prestigious awards honoring scientists who have made ... in a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition ...
(Date:10/9/2017)... , ... October 09, 2017 , ... ... four-tiered line of medical marijuana products targeting the needs of consumers who are ... of Kindred takes place in Phoenix, Arizona. , As operators of two successful ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):